Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Interferon-beta-1b - Toray/Daiichi Sankyo

Drug Profile

Interferon-beta-1b - Toray/Daiichi Sankyo

Alternative Names: DL-8234; Feron; Interferon-beta-1b

Latest Information Update: 04 Nov 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Toray
  • Developer Daiichi Sankyo Company; Toray
  • Class Antineoplastics; Antivirals; Interferons; Recombinant proteins
  • Mechanism of Action Immunomodulators; Interferon beta stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Brain cancer; Glioblastoma; Hepatitis B; Hepatitis C; Malignant melanoma
  • Registered Liver cirrhosis
  • Discontinued Age-related macular degeneration; Liver cancer

Most Recent Events

  • 24 Mar 2015 The product is approved for Cirrhosis in Japan
  • 16 Oct 2009 Registered for Hepatitis C in combination with ribavirin in Japan (IV)
  • 03 Apr 2006 Daiichi Pharmaceutical has merged with Sankyo to form Daiichi Sankyo Inc
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top